Communication of Nonefficacy Benefits of New Drugs Approved on the Basis of Noninferiority Trials Alone
This cohort study of FDA- and drug sponsor –written communications evaluates the communication of nonefficacy benefits of new drugs approved on the basis of noninferiority trials alone.
Source: JAMA Internal Medicine - Category: Internal Medicine Source Type: research
More News: Internal Medicine | Study